LifeStance Health Group (LFST) Expected to Announce Quarterly Earnings on Wednesday

LifeStance Health Group (NASDAQ:LFST) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect LifeStance Health Group to post earnings of $0.0539 per share and revenue of $378.5140 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:30 AM ET.

LifeStance Health Group Trading Up 0.1%

Shares of LifeStance Health Group stock opened at $7.04 on Wednesday. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The business has a 50 day moving average price of $7.08 and a 200 day moving average price of $6.06. The company has a market capitalization of $2.74 billion, a P/E ratio of -234.67 and a beta of 1.12.

Insiders Place Their Bets

In other news, insider Lisa K. Miller sold 57,240 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $6.43, for a total transaction of $368,053.20. Following the completion of the sale, the insider directly owned 261,292 shares of the company’s stock, valued at $1,680,107.56. The trade was a 17.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Bessler sold 119,942 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the transaction, the director directly owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 327,326 shares of company stock valued at $2,259,317 over the last quarter. Company insiders own 6.60% of the company’s stock.

Institutional Trading of LifeStance Health Group

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada increased its position in LifeStance Health Group by 63.4% during the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after purchasing an additional 27,244 shares in the last quarter. AQR Capital Management LLC grew its stake in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after acquiring an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after acquiring an additional 11,331 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of LifeStance Health Group by 10.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after acquiring an additional 51,154 shares during the period. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. BMO Capital Markets started coverage on shares of LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 target price for the company. BTIG Research raised their price target on shares of LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Finally, Barclays began coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.